Wuhan Hvsen Biotechnology Co Ltd (300871.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE1000047H6
Wuhan Hvsen Biotechnology Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.20 bn CNY | 1.68 bn CNY |
| Gross profit | 194.72 m CNY | 520.99 m CNY |
| Operating income | -29.09 m CNY | 302.25 m CNY |
| EBIT | 14.04 m CNY | 302.27 m CNY |
| Net income | -20.16 m CNY | 253.16 m CNY |
| Diluted EPS – continuing operations | -0.12 CNY | 1.25 CNY |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildipirosin. It produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founded in 2002 and is based in Wuhan, China.
More stocks
- TrueLight (3234.TWO)
- Ponce Financial Group, Inc. (PDLB)
- Orange County Bancorp, Inc. /DE/ (OBT)
- goeasy Ltd (GSY.TO)
- Mega-info Media Co.Ltd. (301102.SZ)
- Shanghai Golden Bridge (603918.SS)
- Xiamen Insight Investment Co Ltd (000526.SZ)
- Hangzhou Flariant Co Ltd (605566.SS)
- Hangzhou Huasu Technology Co. Ltd. A (301157.SZ)
- REGENXBIO Inc. (RGNX)
- Group Up Industrial Co., Ltd. (6664.TWO)
- Shenyu Communication Technology Inc (300563.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.